June was an exciting month across the life science market, with multiple breakthroughs and key funding rounds shaping the future of the industry. In this roundup, Invenia Group Consultant Katie Davis covers the most important updates – from advancements in diagnostics to pioneering drug development efforts, highlighting the companies that are driving the change. You can subscribe to monthly biotech funding updates over on LinkedIn to keep up to date with the ever-growing market.
Acquisitions, spin outs and expansions
23andMe received court approval to sell its assets to TTAM Research Institute, led by cofounder Anne Wojcicki, following a $305M winning bid that beat Regeneron’s $256M offer.
Illumina is acquiring SomaLogic proteomics tech and other assets from Standard BioTools for $350M, with up to $75M in milestones payments, plus future assay payments, and a 10-year 2% royalty.
STEMCELL Technologies acquired UK-based Cellular Highways from TTP Group, adding advanced cell sorting tech for applications in CGT, drug discovery, and fragile cells.
Prenetics is selling its majority stake in ACT Genomics to Delta Electronics for ~$46M, finalizing Prenetics’ shift to consumer health and supporting Delta’s biomedical expansion.
bioMérieux is acquiring Day Zero Diagnostics, Inc assets for ~$25M to strengthen its infectious disease diagnostics using NGS technologies.
Bruker is acquiring Austria-based biocrates life sciences ag to expand its mass spec and multiomics metabolomics portfolio.
Hera Biotech has acquired HeraFem®, a POC cervical cancer diagnostic device from Hera Diagnostics, expanding its platform beyond endometriosis and boosting global access to lab-independent women’s health diagnostics.
Nicoya has acquired UK-based Applied Photophysics, a long-established provider of biophysical characterization tools, expanding Nicoya’s portfolio in drug discovery and development.
Thermo Fisher Scientific is exploring the sale of parts of its diagnostics unit, including its microbiology division, valued at ~$4B. Advisers have been engaged to gauge private equity interest.
Enzo Biochem Inc signed an agreement to be acquired by investment firm Battery Ventures in an all-cash transaction valued at roughly $37 million.
Moss Genomics signed a nonbinding term sheet to take a non-controlling equity stake in Genomes.io, a supplier of blockchain-based DNA data storage and sharing services.
QuidelOrtho announced that it will discontinue development of its Savanna molecular diagnostic system and that it aims to acquire UK-based LEX Diagnostics for up to $140 million.
Avance Biosciences, Inc. has launched its NGS Center of Excellence in Houston to centralize and expand sequencing services across research, clinical, and GMP testing for biologics and cell/gene therapies.
Collaborations and partnerships
Platomics and Sequentia Biotech have partnered to streamline clinical diagnostics by combining regulatory workflow management with AI-driven omics analytics.
n6 welcomed new distributors including GeneTiCA Group (Czech Republic, Slovakia, Hungary, Romania, Slovenia & Poland), Witec AG (Switzerland), TrendBio Pty Ltd (Australia and New Zealand) and Rhenium Group (Isreal).
Alida Biosciences announces its first official service provider: the GARP Core at Baylor College of Medicine. This new service offering is powered by AlidaBio’s EpiPlex™ Platform.
Agenus and NOETIK announced a research collaboration to Develop AI-enabled predictive biomarkers for BOT/BAL using foundation models of virtual cell biology.
SeqOne and Agilent Technologies announce strategic collaboration to advance liquid biopsy data analysis for oncology applications.
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center | Helmholtz Munich collaboration to build the foundation of a single cell atlas, that will profile 100s of millions of single cells with AI to predict how tumors adapt in response to treatments.
Parse Biosciences and the Icahn School of Medicine at Mount Sinai have partnered on a single-cell sequencing-based study of Alzheimer’s and Parkinson’s diseases.
Lumea partnered with Paige to expand the integration and impact of AI-powered workflows across pathology practices.
Genomics and Novo Nordisk are partnering to use genetic insights for obesity prevention, focusing on early intervention based on an individual’s genetic risk rather than just treatment.
RayBiotech has partnered with life science consultancy firm Venebio Group, LLC to offer drug and diagnostic development services.
Enhanced Genomics partnered with the ALBORADA Drug Discovery Institute at the University of Cambridge to identify therapeutic targets for Alzheimer’s disease using a multiomics approach.
Galatea Bio Inc. and Fabric Genomics have entered into a strategic partnership to integrate their respective technologies in developing genetic disease risk tests.
The Align Foundation partnered with ATCC to create public, AI-ready microbial datasets.
Gene Solutions has signed separate memoranda of understanding with two China-based diagnostics companies to commercialize its cancer care technologies in the Asian country.
Intelliseq and Genomenon, Inc announced a partnership to integrate elements of their respective platforms.
BioAge Labs has expanded an alliance with Age Labs AS to analyze additional samples from a Norwegian biobank to help identify new drug targets for age-related diseases.
Sphere Bio has entered an exclusive distribution partnership with China’s Redbert Biotechnology.
UGenome AI will integrate PlexusDx’s pharmacogenomic testing platform into its personalized medicine offerings under a strategic collaboration.
Tempus AI will collaborate with Northwestern University – The Feinberg School of Medicine’s Abrams Research Center on Neurogenomics to use AI for Alzheimer’s research.
Bayer has extended a long-running genomics research collaboration with the Broad Institute of MIT and Harvard for another five years. The aim of the partnership is to identify therapeutic targets for cardiovascular disorders such as dilated cardiomyopathy.
Bayer has extended its genomics research collaboration with the Broad Institute of MIT and Harvard for five more years, focusing on identifying therapeutic targets for cardiovascular disorders.
MGI has partnered with:
Asia PGI, which is part of the Duke-NUS Center for Outbreak Preparedness, to enhance pathogen genomic sequencing efforts across Asia.
NEGEDIA a to expand access to DNBSEQ™-powered genomic sequencing and Stereo-seq spatial transcriptomics for precision medicine and biomedical research in Italy.
Alamar Biosciences, Inc. has teamed up with the Alzheimer’s Disease Data Initiative and Gates Ventures to create a clinically annotated plasma proteome atlas for Alzheimer’s disease and related dementias.
Molecular Instruments and Alpenglow Biosciences announced a partnership that enables high-resolution, three-dimensional RNA imaging in intact biological specimens.
Taconic Biosciences entered into an exclusive license agreement with Helmholtz Munich to provide preclinical researchers with CRISPR gene editing services.
Elucidata has formed a strategic partnership with Sapien Biosciences to convert Sapien’s biobank assets into data products accessible by AI for use in drug and diagnostic development.
Aitia partnered with Gustave Roussy to conduct research into the underlying causes of cancer for the purpose of developing new therapies.
Transcripta Bio io has partnered with Microsoft Research to identify new disease-gene associations using large-scale transcriptomic data.
QIAGEN announced that it has launched a third-party partnering program for its clinical digital PCR platform and signed an agreement with the program’s inaugural partner Gencurix, Inc.. They also signed partnerships with:
Foresight Diagnostics to codevelop a NGS-based MRD companion diagnostic kit for lymphomas and other malignancies.
Incyte to develop a NGS companion diagnostic for detecting clinically relevant gene alterations in a subset of hematologic malignancies.
Tracer Biotechnologies to co-develop and commercialize MRD assays for solid tumours.
PacBio and Target ALS have partnered to sequence over 6,000 genomes from ALS patients and healthy controls to uncover genetic variants linked to the disease.
Oxford Cancer Biomarkers and Mira Precision Health partner to commercialize OCB’s ToxNav test for identifying people at high risk of severe toxicity to 5-fluorouracil (5FU) and Xeloda (capecitabine) treatment.
EDX Medical Group has a signed a memorandum of understanding with UK-based Spire Healthcare Group plc around diagnostic products and testing services.
Regeneron Genetics Center (RGC) has launched a large-scale proteomics research project involving nearly 200,000 patient samples from the Geisinger Health Study. It has chosen Olink Proteomics’ Explore HT proteomics platform and Ultima Genomics’s UG 100 ™ sequencing platform to support the project.
Nikon Instruments and Astellas Pharma have partnered to provide SakuLab™-Cambridge resident companies with access to Nikon’s advanced imaging technologies and BioImaging Lab USA services.
Fujirebio has partnered with Stanford Medicine to advance infectious disease testing using ultrasensitive immunoassays powered by single-molecule counting tech from its subsidiary Fluxus, Inc., aiming to improve clinical decisions and therapeutic research.
Product updates
Slingshot Biosciences launched TruCytes™ Potency, a new class of biomarker cell mimics specifically designed for functional CAR-T potency assays.
28bio launched the Nexon™ neurotechnology platform, combining tissue engineering, neural interfacing, and AI to replicate complex brain functions at scale.
Molecular Instruments introduced the HCR™ Pro RNA-ISH for Manual Workflows, offering high sensitivity for low-abundance targets and challenging samples.
Platomics, in partnership with @Biomed Austria, launched the PlatoX® Academy, providing training and certification to help labs navigate complex regulatory frameworks like IVDR and ISO 5649.
Biotium unveiled the ExoBrite™ CD9/CD63/CD81 Antibody Cocktails for efficient phenotyping and high-coverage staining of extracellular vesicles by flow cytometry.
Araceli Biosciences unveil (at SLAS) the Endeavor Ultra, Endeavor Core, and Endeavor Pro, their boldest leap yet in high-content imaging.
Tempus AI launched xM for TRM, a RUO liquid biopsy assay to monitor molecular response to immune-checkpoint inhibitors in advanced solid tumors.
Emulate, Inc. launched the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run.
STEMCELL Technologies launched the STEMprep™ Tissue Dissociator System, that automates and standardizes tissue dissociation to streamline single-cell preparation for research.
Simulations Plus, Inc. released ADMET Predictor® 13, the latest version of its ML-powered platform for molecule design, optimization, and selection in drug discovery.
Genomics launched its Health Insights test across Great Britain, the first UKCA marked and MHRA registered product that combines genetic and clinical factors to predict and prevent common diseases.
ZeptoMetrix launched NATtrol Influenza A H5N1 Quantitative Stock for molecular diagnostic quality assurance.
IonOpticks launched the 4th Generation of its Aurora Series chromatography columns, enhancing robustness, longevity, and reproducibility.
Miraomics, Pythia Biosciences and LatchBio released a 30-million-cell atlas covering over 150 indications, 200 tissue types, and 27 measurement technologies from public sources.
LatchBio also launched a suite of agentic molecular curation tools that improve per-dataset curation times by around 40x and increase annotation quality and consistency.
Devyser launched Devyser HLA Loss, a RUO NGS assay designed to enable investigators to detect HLA loss in post-transplantation studies.
Alithea Genomics launched Mercurius Total Drug-seq, a library preparation kit for full-length transcriptome profiling, designed for high-throughput drug screening and target validation.
Singular Genomics is expanding access to its G4X platform, following a successful early access phase, by adding 10–15 sites to its Spatial Innovation Network to accelerate spatial multiomics research.
GoPath Diagnostics launched DiabetesNow, a comprehensive genetic test for the diagnosis, classification, and management of diabetes.
Phase Genomics launched its ProxiMeta Starter and Elite Bundles for genome- and mobilome-resolved metagenomics.
Integrated DNA Technologies launched:
PrimeTime Influenza Kit and PrimeTime Research Pathogen Panels.
A synthetic biology customer solutions program designed to provide custom-tailored offerings beyond the company’s catalog synthetic biology products.
PEPperPRINT GmbH launched its cLIFT (combinatorial laser-Induced forward transfer) peptide microarray platform.
Seek Labs launched BioSeeker, an AI discovery engine that integrates real-world genomic data and proprietary data to identify high-potential target sites for pathogen therapeutics.
Eclipsebio launched the EVerse RNA dataset portfolio, aiding therapeutic development from target discovery to drug design.
Sequentify and Bio Molecular Systems launched the InfiniSeq Myra protocol for automated NGS library preparation.
BD unveiled the BD FACSDiscover A8 Cell Analyzer with BD SpectralFX Technology, enabling flow cytometry analysis of 50+ cell characteristics.
Nucleus Genomics launched Nucleus Embryo genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo.
Mission Bio introduced a Single-Cell Genotype and Targeted Gene Expression Assay for its Tapestri platform, enabling simultaneous profiling of over 10,000 single cells.
Myllia Biotechnology launched the Vista platform for genome-wide CRISPR screens in primary human macrophages and dendritic cells
Thermo Fisher Scientific launched:
Orbitrap Astral Zoom and Orbitrap Excedion Pro mass spectrometers.
Several software releases, including its Chromeleon 7.4 (for Mass Spec), Proteome Discoverer 3.3 (targeted proteomics workflows and mass spec) and Compound Discoverer 3.5 (for lipid analysis)
Bruker launched:
Several mass spectrometers with Athena Ion Processor (AIP) technology, including the timsUltra AIP for single-cell proteomics and immunopeptidomics, timsOmni for proteomics workflows, and timsMetabo for metabolomics.
The proteoElute nanoLC system and a new PepSep Advanced nanoLC column, improving peptide and protein identification.
SCIEX launched the ZenoTOF 8600 system, offering 10x the sensitivity of its previous models and enabling ZT Scan DIA 2.0 acquisition mode. The instrument provides scan speeds of up to 858 Hz.
Seer introduced its Proteograph One Assay and SP200 Automation Instrument, which together offer an advance in the company’s assay simplicity and throughput.
Evosep Biosystems launched the Evosep Eno separations platform, offering standardized methods for processing 30-500 samples per day with improved performance.
Revvity released three Mimix IVD reference standards for monitoring NGS and droplet digital PCR assays for somatic mutation detection.
BioIVT launched Visionaire™, a new solution designed to tackle reproducibility, scalability, and accessibility challenges in AI-driven target discovery, drug development, and digital pathology.
Mursla Bio launched its AI Precision Medicine Platform and a preprint validating a method to isolate hepatocyte EVs for organ-specific profiling.
Accreditations & regulatory updates
G2M | Next Generation IVD solutions for Genomics OnePCR system has been registered as 510(k) exempt with the US FDA.
Diasorin received FDA 510(k) clearance for a syndromic panel to detect Gram-positive bloodstream infections and drug resistance biomarkers.
LEX Diagnostics submitted a POC PCR system for influenza A, B, and COVID-19 to the FDA for 510(k) clearance and CLIA waiver.
Natera’s Signatera Genome circulating tumor DNA test for MRD is now broadly covered by Medicare for several indications.
Biocartis gained IVDR Class C certification for a companion diagnostic test for non-small cell lung cancer treatment decisions.
LabPMM GmbH received NY State approval for its NPM1 MRD assay for acute myeloid leukemia treatment guidance.
Cepheid’s Xpert HIV-1 Viral Load XC assay received a medical device license from Health Canada.
Sysmex America, Inc. received FDA clearance for the CN-6000™ Automated Blood Coagulation Analyzer.
Funding updates
Pre-seed funding:
Sortera Bio (England) raises £7.5m pre-seed to power AI models for drug discovery.
Seed funding:
LayerLogic AB (Sweden) raises €470K in Pre-seed funding to develop graphene-based biosensors for rapid pathogen detection.
Oria Bioscience (France) raises €2.7M in seed funding.
OutSee (England) raises £1.8M seed funding to expand therapeutic pipeline using AI.
UTOPIA THERAPEUTICS (India) raises $1.5M in seed funding for next-generation vaccine development.
LogicFlo AI (USA) raises $2.7 million in seed funding to optimize regulatory and operational workflows using AI.
OrisDX (IL, USA) raises $4 million in seed funding to support the launch of its saliva-based molecular test for oral cancers.
Spica Therapeutics (Belgium) raises €10M in Seed round for therapeutics.
Elkedonia (France) closed €11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders.
Laverock Therapeutics (England) extends its seed round to more than £20m to support disease-responsive advanced therapies development.
Series A funding:
Rebel Medicine (UT, USA) raised $6M in Series A funding to support a Phase 2 trial of Alevatrix™ in bunionectomy patients, following its recent IND application.
Infinity Bio, Inc. (MD, USA) closes an $8 million Series A funding round and acquires assets of immune profiling firm Serimmune.
Kamari Pharma (Israel) announced closing of $23 Million Series A financing to advance its first-in-class oral TRPV3 inhibitor for rare genetic skin diseases
Portal Biotech (England) raises $35M in Series A funding to commercialize world’s first full-length single-molecule protein sequencer
Parallel Bio (MA, USA) raises $21 million in Series A funding for advance human-first drug discovery.
Mosanna Therapeutics (CA, USA) completes an $80 million Series A funding round for neuropsychiatric treatments.
Draig Therapeutics (Wales) raises $140 million in Series A capital to develop novel treatments for neuropsychiatric conditions.
Antares Therapeutics (MA & CA, USA) launched with $177 Million Series A financing, to develop first-in-class precision medicines for cancer and other serious diseases.
Series B funding:
Actio Biosciences, Inc. (CA, USA) raises $66M in Series B funding for genetics and precision medicine.
SpliceBio (Spain) closes a $135 million Series B for the phase I/II trial of SB-007 in Stargardt’s disease treatment.
Series C funding:
GeneCentric (NC, USA) announces the initial closing of an $8 million Series C funding round for ctDNA liquid biopsy platform.
Qure Biotechnology (China) completes a Series C1 financing round raising nearly CNY 100 million (appro. $14 million) for clinical trials and antibody therapeutics.
Arima Genomics (CA, USA) closed a $22 million Series C funding round and appointed a new CEO, marking a strategic shift to focus on transforming oncology testing.
Antheia, Inc. (CA, USA) raises $56 million in Series C funding for pharmaceutical ingredient manufacturing.
Series D funding:
SpyGlass Pharma, Inc. (CA, USA) raised $75 million series D funding to advance its long-term drug delivery platform for glaucoma patients.
Neuron23 (CA, USA) raised $96.5M in Series D funding and dosed the first patient in its global Phase 2 NEULARK trial of NEU-411, a brain-penetrant LRRK2 inhibitor for early Parkinson’s disease.
Government & research grants:
MetasTx LLC (PA, USA) secures a $500,000 SBIR grant from the National Cancer Institute for developing a companion diagnostic test for prostate cancer.
Tagomics (England) is awarded £860k from Innovate UK to develop a diagnostic test for early detection and treatment of colorectal cancer.
Scope Biosciences B.V. (The Netherlands) secures €1 million in follow-on investment to scale its molecular diagnostics platform.
Linear Diagnostics (England) is awarded £1 million from the National Institute for Health and Care Research to support rapid diagnostic development for sexually transmitted infections.
MicroPure Genomics Inc. (CA, USA) receives a $1.25 million grant from the National Science Foundation to continue its sample prep technology.
Mitra bio (England) receives €2.5 million from European Innovation Council (EIC) Accelerator.
Nanostics Inc. (Canada) receives C$3.8 million grant to boost adoption of its ClarityDx prostate cancer risk tool.
Pixelgen Technologies (Sweden) secures €12.5M in grant and equity funding from EIC Accelerator.
Single Technologies (Sweden) secures €12.5M in grant and equity funding from EIC Accelerator.
UK Biobank receives £20 million from the UK government to support the Pharma Proteomics Project profiling the proteomes of 500,000 individuals.
City of Hope (CA, USA) received $23.7 million from ARPA-H, to map biomarkers linked to treatment resistance in patients with common lung cancer.
Private funding & series rounds:
Huna (Brazil) raises $1.5M to expand AI-powered cancer diagnostics platform.
Epigenica (Sweden) raises $2.2 million to support growth and commercial expansion.
Kiin Bio (England) raises $2.2M to launch the Virtual Scientist Platform for drug discovery.
Ryght AI (CA, USA) raises $3 million to use ‘agentic AI’ to automate processes at trial sites.
32 Biosciences “Three Squared” (IL, USA) raises $6 million in private funding to support the development of its first gut microbiome products.
Enterome (France) raised $19 million in a new private financing to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma.
Visby Medical (CA, USA) raises about $55 million in a recent financing round, potentially reaching $65 million.
Equity & convertible notes:
Tempus AI (IL, USA) plans to sell $400 million in convertible senior notes, with proceeds primarily going toward paying down debt.
ADC Therapeutics (Switzerland) announces $100 million private placement extending expected cash runway into 2028.
IPO:
Caris Life Sciences (TX, USA) prices $494M IPO.
If you’re a life science startup looking for talent, or you’d like to learn more about our recruitment services, submit your vacancy and a recruitment consultant that specialises in your field will be in touch shortly.
Alternatively, are you seeking advice on your next move? We’re here to help. Register with us today to schedule a confidential discussion about your career prospects.
